Business
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics\n \n \nEndonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics\n\nNext-Generation Biologics Include Cell Therapies and Human Biomolecules Produced by Electromagnetic Stimulation of Adult Stem Cells\n\n \n LOS ANGELES, CA--(Marketwired - Aug 10, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that it has filed a patent titled, \"Methods and Compositions for Treating Chemical and Radiation Injuries.\" The patent filing covers the production of biologics, including cell therapies and biomolecules created using a proprietary bioreactor and their corresponding administration as a therapeutic for treating chemical and radiation injuries, including chemotherapy and radiation exposure.\n This patent filing is a continuation-in-part of the patent described in the announcement dated August 9, 2016.\n Next-Generation Biologics, including growth factors and cell therapies seek to overcome the shortcomings of current therapies, including inconvenient dosing, immunogenicity and other side effects. Visiongain predicts a market for next-generation biologics of $30 billion with five blockbuster biologics being developed by the year 2024.\n Alan Collier, Endonovo's Chief Executive Officer, commented, \"Now that we have an issued patent covering our proprietary process, which effectively trains cells to secrete therapeutic proteins, such as G-CSF, GM-CSF, EPO and IL-2, we can begin pursuing several indications using our Cytotronics platform.\"\n \"Many of the biomolecules that we can train cells to produce are used to promote the growth of specific blood cells, including, blood-forming stem cells, infection-fighting white blood cells and oxygen carrying red blood cells. We believe that we can also expand blood-forming stem cells to replace damaged or lost cells and train and enhance them using our proprietary process to deliver a cocktail of therapeutic proteins,\" said Mr. Collier. \n About Endonovo Therapeutics\n Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-applications in cell therapies and non-inva...